Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Japan Graft Versus Host Disease (GVHD) Market Insights, Epidemiology and Market Forecasts, 2023 - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecast - 2023 - Japan" drug pipelines to their offering.

Japan Graft versus Host Disease (GVHD) - Market Insights, Epidemiology and Market Forecasts, 2023 report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations (HSCTs) and Graft Versus Host Disease (GVHD) based upon the sub-types of GVHD along with the type of donor involved in the HSCTs, for the forecast period (2013-2023). The report also includes global market size of the Graft Versus Host Disease (GVHD) for Japan.

GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations (HSCTs). Our forecasts predict an on-going increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants (HSCTs) shall increase at a Compound Annual Growth Rate (CAGR) of 2.73% from 2013-2023 and reach up to 7,025 cases in the year 2023.

The incident rate of GVHD in unrelated donor (URD) is much higher in comparison to the sibling donors (SD), irrespective of the sub-types i.e., acute GVHD (aGVHD) or chronic GVHD (cGVHD). As per our forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 2.88% and 1.57%, respectively, from 2013-2023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 2.88% and 1.57%, respectively, by the end of the year 2023.

The market size of GVHD mainly comprises of the off-label biologics. Many companies are working on the development of targeted therapy and in the near future, these drugs may create an impact on the overall market size of GVHD. Estimates suggest that the forecasted market size of Graft Versus Host Disease (GVHD) in Japan shall increase at a CAGR of 4.80% from 2013 to 2023.

Key Topics Covered:

  1. Graft Versus Host Disease (GVHD)
  2. Disease Definition
  3. Disease Types
  4. Acute GVHD
  5. Chronic GVHD
  6. Grades of GVHD
  7. Pathophysiology
  8. Risk Factors for GVHD
  9. Diagnosis
  10. Epidemiology and Patient Population
  11. Key Points
  12. Assumptions and Rationale
  13. Treatment Algorithm
  14. Guidelines and Recommendations for Treatment of GVHD in Japan
  15. Current Unmet Needs of Graft Versus Host Disease (GVHD)
  16. Marketed Drugs

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/fjr896/graft_versus_host

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005508/en/

Business Wire
www.businesswire.com

Last updated on: 17/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.